The NEJM’s 16 July 2026 issue includes findings from phase 3 trials on multiple myeloma treatment duration, antiplatelet therapy, and a drug for lupus.
The New England Journal of Medicine has posted details of its latest issue, covering results from three separate clinical studies across blood cancer, heart disease, and autoimmune conditions. The announcement was made on the journal’s official account on 16 July 2026.
The issue includes findings from the ENDURANCE trial, a phase 3 study examining how long patients with multiple myeloma — a cancer of plasma cells found in bone marrow — should continue maintenance therapy after initial treatment. Phase 3 trials are the large-scale human studies that regulators typically require before approving changes to standard care.
A second study, the DAPT-MVD trial, looks at extended dual antiplatelet therapy (DAPT) — a combination of two medicines that reduce the risk of blood clots forming on artery walls, commonly used after heart stents or cardiac events.
The third paper covers obinutuzumab, a drug being assessed for efficacy and safety in patients with active systemic lupus erythematosus (SLE), a long-term autoimmune condition in which the immune system attacks healthy tissue throughout the body.
None of the three studies has yet resulted in changes to NHS treatment guidelines. Patients in Kent with questions about their current treatment for any of these conditions should speak to their GP or specialist rather than acting on trial findings alone.
Call NHS 111 if you need urgent medical advice outside GP hours.
Source: @NEJM
New England Journal of Medicine Publishes Three Major Clinical Trial Results Quiz
5 questions